The Precision Medicine Company

Developing microbiome-based predictive diagnostic and companion therapeutic products to enable safer and more efficacious drug therapies

AlphaBiomics awarded NIHR i4i Connect grant for development of RxSelex™ 2.0

 Read more here

Funded by